FOXA1 and prostate carcinoma: After iBET-151 treatment, H3K27ac signals associated with FOXA1 were markedly reduced in both PC-3 and DU145 cells (Fig. 4L–O), supporting FOXA1 as a direct SE target in prostate cancer progression.